Fingerprint
Dive into the research topics of 'Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Teri J. Mauch, Michael R. Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P. Dixon, Katherine Garlo, Christoph Gasteyger, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P. Pham, Tara Symonds, Ioannis Tomazos, Yan Wang
Research output: Contribution to journal › Article › peer-review
4
Scopus
citations